Servier Enters Into a Type 2 Diabetes partnership With Canadian Firm Prognomix Inc.

SURESNES, France and MONTRÉAL, November 8, 2011 (ots/PRNewswire) -

Les Laboratoires Servier, France (Servier) and Prognomix Inc.,
Canada (Prognomix) announced today that they have entered into a
research and development agreement aimed at identifying novel targets
as part of programs meant to develop innovative type 2 diabetes and
metabolic disease treatment.

This collaboration will rest on the discovery platform developed
by Prognomix. This platform comprises genomic and bioinformatic
technologies, a database of phenotypic and genotypic data and an
assembly of results of the analysis of these data that are at the
foundation of a knowledge base that will be exploited by the
partners. This knowledge base was developed using, among other, the
data collected during ADVANCE, the largest clinical study ever
conducted on Type 2 diabetes and of which Servier was the main
sponsor.

As part of the agreement, Servier will make a contract signature
fee payment and will be granted options to obtain rights to use the
results of the collaboration.

According to Dr. Pavel Hamet, President of Prognomix, " Closing
of this agreement represents an important step in the development of
Prognomix and confirms the value of the knowledge base that we have
developed. We are happy to initiate this collaboration with Servier,
a well known and very innovative pharmaceutical company and we are
excited by the opportunities it represents ".

According to Dr. Emmanuel Canet, President of Research and
Development at Servier, " This partnership confirms Servier interest
for well validated biomarkers, allowing for the identification of the
patients who will benefit the most from Servier therapeutic
innovations ".

About Prognomix Inc.

Prognomix Inc. is a privately held Personalized Medicine company
incorporated in Montreal in 2005 and focused on discovery and
clinical application of genomic signatures predictive of
susceptibility to diseases, their complications and individual
therapeutic responsiveness. The company has made significant progress
in the identification of the genomic features associated with
complications of type II diabetes (T2D). Based on these findings
Prognomix has developed a prototype of a molecular diagnostic kit
that will include clinical, genomic and epigenomic markers

About Les laboratoires Servier

Servier is a leading French independent pharmaceutical company
and the second French pharmaceutical company worldwide. Its
affiliates are present in 140 countries and account for 20,000
employees including 3,000 in research and development.
http://www.servier.com

For further information:
For Prognomix :
Normand Balthazard, CEO
+1-514-248-7789
nbalthazard@gmail.com
For Servier :
Direction de la Communication Institutionnelle
Tél : +33(0)1-55-72-60-37

ots Originaltext: Prognomix Inc
Im Internet recherchierbar: http://www.presseportal.de

Contact:
.